And we will keep adding additional centers to fill out the geographic gaps that we're having across the U.S. And with that, minimize the travel distances for patients to access therapy.

Nov 12, 2025 / receipt, needs a key / Dr. Christian Eiten, CEO | earnings call 2025-11-12 | transcript 2e888b5d-10c4-4a21-aaa9-a2731a027582 | chars 4884-5069 | segment 4

And one of the things that we obviously learned that many of you do know, given that many of you are traveling internationally quite a bit, is one of the things that we obviously have in our favor is that international flights have priority. That's where the airlines make most of their money. And those flights go on time. And that actually has been a huge asset through the pandemic and actually gave us not only a good ability to serve, but an actual advantage in terms of the robustness and stability of our logistics.

May 17, 2024 / receipt, needs a key / Christian Eiten, CEO | earnings call 2024-05-17 | transcript 4becd2cf-a3cb-4774-9ca4-fa4ba2f0838a | chars 9835-10357 | segment 10

Obviously, you've seen the data for the interim analysis. Obviously, we have a very high level of response rate. We have an excellent safety profile. So I think overall we do know that the program has done really well in this population and during this period of time. Now, one of the key things that we're in the process of evaluating, but we don't have the full answers at this point, is what are sort of the individual impact that we could see during that period of time attributable to the conditions that we were having, you know, restrictions on travel for patients which led to delays, for some of the patients to actually get access to treatment, et cetera.

May 4, 2023 / receipt, needs a key / Christian Eiten, CEO | earnings call 2023-05-04 | transcript 806e012c-23f5-487f-9bc9-e30cf3ada179 | chars 44607-45272 | segment 45

With the expected opening of travel for vaccinated people between the US and Europe, we also expect flight operations to start to gradually normalize, which will relax the pressure on logistics.

May 6, 2021 / receipt, needs a key / Dr. Christian Eiten, CEO | earnings call 2021-05-06 | transcript 8a6969f5-6205-4cfa-9c92-3fcaa84f2ce0 | chars 2902-3096 | segment 2

The increase in research and development cash costs of $33.5 million consisted primarily of, firstly, an increase of $8.8 million in compensation and employment-related costs, that's net of lower travel costs, due to an increase in the employee headcount to support the advancement of our product candidates in clinical development. The lower travel costs obviously due to the COVID-19 pandemic.

Mar 4, 2021 / receipt, needs a key / Andrew, CFO | earnings call 2021-03-04 | transcript a0a45329-d602-4074-a318-982ac3db8c8f | chars 19528-19923 | segment 20

Senior Manager, Organisation Development | {"ats": "workday", "city": null, "state": null, "job_id": "/job/UK---London-White-City/Senior-Manager--Organisation-Development_JR100164", "remote": false, "

company_statement / Sep 16, 2026 / receipt

Executive Director / Vice President, Business Development | {"ats": "workday", "city": null, "state": null, "job_id": "/job/UK---London-White-City/Executive-Director---Vice-President--Business-Develop

company_statement / Sep 9, 2026 / receipt

*Assumes pediatric label expansion

ir_statement / Sep 8, 2026 / receipt

B-ALL with pediatric label expansion

ir_statement / Sep 8, 2026 / receipt

Opportunity in U.S. to be the preferred treatment for all age groups in r/r

ir_statement / Sep 8, 2026 / receipt

Based on current operating plans, including anticipated AUCATZYL® net revenues, Autolus expects that its current and projected cash, cash equivalents and marketable securities will be sufficient to fu

ir_statement / Sep 8, 2026 / receipt

Turn to positive gross margin occurred in Q1 2026 and is expected to steadily improve

ir_statement / Sep 8, 2026 / receipt

Manufacturing Life Cycle Strategy: Opportunities for Innovation to Improve Margins

ir_statement / Sep 8, 2026 / receipt

Fast, reliable and consistent product delivery

ir_statement / Sep 8, 2026 / receipt

Manufacturing success rate >90%

ir_statement / Sep 8, 2026 / receipt

No capacity limitations

ir_statement / Sep 8, 2026 / receipt

Exploration of alternate market access mechanisms in 2026

ir_statement / Sep 8, 2026 / receipt